Verastem
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-676...
Latest News
11 hours ago · marketbeat.com
Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials AdvanceVerastem NASDAQ: VSTM is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent launch as it awaits midstage trial results.
5 days ago · marketbeat.com
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval PathVerastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile executives said was comparable to the 600-milligram dose.
6 days ago · marketbeat.com
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial PlansVerastem NASDAQ: VSTM is advancing its experimental KRAS G12D inhibitor VS-7375 toward potential accelerated approval in pancreatic cancer, with plans to expand studies in colorectal and lung cancers, company executives said at an investor event.
10 days ago · marketbeat.com
What Verastem (VSTM) Said on Its Q3 Earnings CallVerastem NASDAQ: VSTM reported $24 million in third-quarter 2026 net product revenue as refills of its ovarian cancer treatment offset a moderation in new patient starts. The company also outlined plans to begin a late-stage pancreatic cancer trial for its experimental drug VS-7375 by year-end.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VSTM